Corvus Pharmaceuticals, Inc. (CRVS) analyst actions
Rating and price-target actions on CRVS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CRVS overview →
4 measured CRVS analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa | Press release | +0.22% | -5.45% | |
| Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) | Press release | -0.11% | +4.51% | |
| Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma | Press release | +0.73% | +13.05% | |
| Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Press release | -0.60% | -9.58% |
Keep exploring
More CRVS: earnings → · SEC filings → · CRVS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Amarin Corporation plc - American Depositary Shares (AMRN) | 211 | +0.30% | 55% |
| BioRestorative Therapies, Inc. (BRTX) | 209 | -0.82% | 38% |
| Journey Medical Corporation (DERM) | 208 | 0.00% | 50% |
| Windtree Therapeutics, Inc. (WINT) | 207 | -1.40% | 27% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.